G12d
Untracked preview. This is not a tracked Signal Bureau entity — the page is generated on request from live coverage search, is not indexed, and carries no editorial curation. Tracked entities live on the Wire.
If G12d is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V. · J Gastrointest Cancer · 2026-09-01
- Dr Huffman on the Mechanism of Action of INCB161734 in KRAS G12D–Mutated Metastatic Pancreatic Cancer - OncLive · KRAS Mutation Research (Google News) · 2026-09-01
- Verastem: A Rare-Disease Launch Is Financing A KRAS G12D Platform (NASDAQ:VSTM) - Seeking Alpha · KRAS Mutation Research (Google News) · 2026-08-31
- DAWN-303 Trial Set to Advance INCB161734 in First-Line KRAS G12D–Mutated Metastatic Pancreatic Cancer - OncLive · KRAS Mutation Research (Google News) · 2026-08-28
- GenFleet Advances KRAS G12D Lung Cancer Drug GFH375 into First-Line Phase II Study - TipRanks · KRAS Mutation Research (Google News) · 2026-08-26
- IDEAYA Biosciences (IDYA) Is Up 5.2% After Genentech KRAS G12D Trial Collaboration News - Has The Bull Case Changed? - Sahm · KRAS Mutation Research (Google News) · 2026-08-21
What the reporting says
It shows up alongside KRAS (60), Lung Cancer (15), Pancreatic Cancer (14), Colorectal Cancer (13).
Two steps out: KRAS Mutant (through KRAS, 46 shared stories on the weaker link); Egfr (through KRAS, 27 shared stories on the weaker link); Immunotherapy (through KRAS, 22 shared stories on the weaker link); Pdac (through KRAS, 19 shared stories on the weaker link).
Tracked since Apr 12, with coverage on 42 separate days — concentrated in Oncology and Pubmed Targeted.